A study by Boils et al. demonstrated that the usage of the PD-1 pathway inhibitor nivolumab contributed to allograft rejection in a renal transplant patient with stage IV squamous non-small-cell lung cancer [28]. Here, PDCD1 is linked to non-small cell squamous lung carcinoma.